FDC346.40

FDC Limited

· Pharma & Health
₹ CrorePeersIOLCPMOREPENLABINNOVACAPORCHPHARMASENORESGUJTHEMRPGLIFESANOFIMcap ₹5,640 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Returns
Return on Common Equity14.5511.7011.3211.32
Return on Assets12.369.839.649.64
Return on Capital Employed13.8411.5211.2311.23
Return on Invested Capital14.1711.6010.9710.56
Margins
EBITDA Margin17.4215.4115.9415.32
Operating Margin15.3712.8613.2113.21
Incremental Operating Margin-16.6825.14
Pretax Margin20.3916.9417.2617.78
Net Income Margin15.7012.6612.9613.36
Net Income to Common Margin15.71
FCF Margin6.5610.480.640.64
Additional
Effective Tax Rate23.0125.3124.8724.89
Dvd Payout Ratio0.0530.4128.79
Sustainable Growth Rate14.548.148.0611.32
Incremental Operating Margin %-16.6825.14-56.34
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.